FDA recommends hydrocodone be classified as Schedule II

Share this article:
FDA recommends hydrocodone be classified as Schedule II
FDA recommends hydrocodone be classified as Schedule II

FDA said Thursday that it will recommend that hydrocodone (Vicodin) and hydrocodone combination products be reclassified to Schedule II. Janet Woodcock, CDER director, who announced the recommendation, stated that FDA has become “increasingly concerned about the abuse and misuse of opioid products, which have sadly reached epidemic proportions in certain parts of the United States.”

According to a statement, the FDA will submit its formal recommendation to HHS for this reclassification in early December. The agency anticipates agreement with its recommendation. Hydrocodone, which is currently Schedule III for “drugs with a moderate to low potential for physical and psychological dependence,” would be placed under Schedule II, which is reserved for drugs with a high potential of abuse and would elevate the drugs' risk factor to that of cocaine, methampethatime and oxycodone—among others.

This change would also reduce the number of refills patients could receive before going back to their doctor, and patients would have to take the prescription to the pharmacy themselves, as opposed to having a doctor phone it in. New regulations would also reduce the supply a patient would receive from a 180-day supply to 90-day, as well as change who can prescribe these drugs—which varies by state—and other changes.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.